Heart Transplant Immunosuppression Strategies at Cedars-Sinai Medical Center

Int J Heart Fail. 2020 Sep 29;3(1):15-30. doi: 10.36628/ijhf.2020.0034. eCollection 2021 Jan.

Abstract

Heart transplant is the optimal treatment for selected patients with end-stage heart failure. Immunosuppression after heart transplantation has significantly reduced the incidence of rejection and improved patient outcomes with the routine use of calcineurin inhibitors. Antimetabolites and proliferation signal inhibitors add to the improvement in patient outcomes as well. The goal of induction therapy is to provide intense immunosuppression when the risk of allograft rejection is highest. Most maintenance immunosuppressive protocols employ a 3-drug regimen consisting of a calcineurin inhibitor, an antimetabolite agent and glucocorticoids. The management of rejection proceeds in a stepwise fashion based on the severity of rejection detected on biopsy and the patient's clinical presentation. This review will cover induction, maintenance, rejection therapy and some special considerations including sensitization, renal sparing protocol, and corticosteroid weaning. It will end in consideration of potential future directions in immunosuppressive strategies to promote patient and graft survival.

Keywords: Desensitization, immunologic; Graft rejection; Heart transplantation; Immunosuppression; Maintenance.

Publication types

  • Review